Αρχική World News How to Make the Most of Your Patient Portal During Cancer

How to Make the Most of Your Patient Portal During Cancer

A patient portal is a secure online website that gives people with cancer convenient, 24-hour access to their personal health information from anywhere with an internet connection. Under the recently enacted 21st Century Cures Act, health care organizations must share medical records electronically to all patients. Because of this, health care users can now read notes recapping their visits to the doctor’s office and look at test results electronically. Most patient portals also include features such as direct and secure messaging, online appointment scheduling, online bill payments, and online prescription refill requests.

Patient portals can be particularly helpful for people who are navigating cancer care. For example, people with cancer and survivors often require lifelong follow-up care and may have specialized treatment and survivorship care plans. Some people with cancer may also require close monitoring for treatment-related side effects, also called toxicities, and may need to have frequent lab or imaging tests. All of this can be more easily managed through the patient portal.

More importantly, research has shown that communication between patients and their health care teams can lead to meaningful improvements in survival and quality of life. By using electronic records effectively, people with cancer can gain a deeper understanding about their health, develop more trust in their providers, and be better prepared to interact with their providers about their care.

Here are some tips for using these patient portals effectively:

  1. Understand that sometimes there is too much information with too little context. Sometimes, patients are notified that their test results are available for review, even before their oncologist is able to access those results. This may lead to confusion and anxiety about your situation. Before you access your test results, talk with your doctor about how and when you’re going to be able to discuss your test results.

  2. If language in your portal is unclear, ask questions. A lot of the notes in your portal may be written using medical jargon and blunt language, as they are meant primarily for a medical audience. However, health care providers are trying to use more supportive language when making notes in a patient’s chart and are hoping to use less confusing medical jargon moving forward. If you have questions about the information you find in your patient portal, talk with your doctor about it.

  3. Know when to expect a response. Most clinics have an established process for answering messages. When you send a message through your patient portal, a nurse might be responding to other messages and might have to forward your message to the doctor for input. Therefore, a response might take up to 48 hours. Also recognize that messages from patient portals are often only monitored during normal clinical hours, so messages sent after hours or on weekends will likely not get read until the next working day.

  4. Never send an urgent message through the portal. If you’re having fevers while on chemotherapy or experience a significant change in your symptoms from what is typical for you, call the doctor’s office immediately.

  5. Messaging on portals works well for straightforward questions. If you want to refill a prescription or ask a question about managing symptoms, using your patient portal to send those messages is convenient and simple. However, it’s very difficult to have more complicated conversations about prognosis or goals of treatment through electronic messaging. Because of this, it is often best to schedule an in-person visit to ask follow-up questions and learn more about your individual situation.

Electronic medical records are extremely helpful for reviewing what you talked about during your in-person visits. They can also help solidify your understanding of the treatment plan. Be sure to take advantage of this resource available to you, and know that we’re learning how to use these technologies together as doctor and patient. 



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling of Breast Implants

In 2013, Kristen Carbone, of Providence, Rhode Island, had a preventative mastectomy to help protect herself against breast cancer after her mother died of...

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen,...

Thanks For Making This GivingTuesday Our Best One Yet!

We set ambitious goals for GivingTuesday, but they were driven by a time of great need. With your help, we hoped to provide food and...

Over 600 people in England set to benefit from innovative lung cancer treatment

<img width="620" height="348" src="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg" class="attachment-featuredImage size-featuredImage" alt="Lung cancer cell" loading="lazy" srcset="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg 620w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-300x168.jpg 300w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-220x123.jpg 220w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18781" data-permalink="https://news.cancerresearchuk.org/2020/09/11/targeted-drug-for-lung-cancer-approved-for-nhs-use-in-england/lung_cell_cropped-hero/"...

Touching a nerve: How neuroscience could advance our understanding of cancer

KTSDESIGN/SCIENCE PHOTO LIBRARY When supporters donate to our work, their combined generosity might lead to a new discovery that inches us closer to, for example,...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of...